Over the last four decades, the prevalence of stone disease in the United States has more than tripled from 3.2% in 1980 to 10.1% in 2016.1 A recent study estimated the prevalence of stone disease to be 10.9% in men and 9.5% in women based on data from the National Health and Nutrition Examination Survey (2017-2018 cycle).2 There are many factors that may contribute to the prevalence of stone disease including obesity, diabetes, history of gout, climate change, and environmental hazards.1,2,3 Patients suffering from an acute episode of stone disease have a number of surgical options available including ureteroscopy (URS), shockwave lithotripsy, and percutaneous nephrolithotomy.4 URS is the most common interventional treatment for stone disease and one of the most frequent surgeries performed in urology.5 From 1996 to 2016, URS had a 250% increase in total number of treatments performed with the share of total treatments increasing by 17%.6 During this same time period, the share of total treatments performed for shockwave lithotripsy and open surgery fell by 14.5% and 12%, respectively while the share for percutaneous nephrolithotomy remained static.6